![]() ![]() All statements other than statements of historical fact are forward-looking statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. ![]() The webcast will be archived on the website following the completion of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at. The dial-in numbers are (833) 614-1409 for domestic callers and (914) 987-7130 for international callers. Outset will host a conference call today at 2:00 p.m. Until then, the company has suspended its prior guidance. The company anticipates an update on the status of the regulatory review process in the third quarter and to provide an update to its 2022 revenue and other financial goals during its next quarterly update in early August. Devices that are already distributed to home users have not been removed and current users can continue to work with their healthcare providers on appropriate treatment.Īs a result of the shipment hold, Outset now expects second quarter 2022 revenue of at least $25 million. The company will continue to market and ship Tablo for use by healthcare professionals in chronic and acute care settings. Outset has not identified any safety issues with Tablo. (Nasdaq: OM) ("Outset" or the "company") today announced it has implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the Food and Drug Administration’s (FDA) review and clearance of a 510(k) the company submitted for changes made since the device’s original March 2020 clearance. SAN JOSE, Calif., June 13, 2022-( BUSINESS WIRE)-Outset Medical, Inc. ![]() Investor Webcast and Conference Call Scheduled for 5:00 p.m. ![]()
0 Comments
Leave a Reply. |